JP2011518178A5 - - Google Patents

Download PDF

Info

Publication number
JP2011518178A5
JP2011518178A5 JP2011505210A JP2011505210A JP2011518178A5 JP 2011518178 A5 JP2011518178 A5 JP 2011518178A5 JP 2011505210 A JP2011505210 A JP 2011505210A JP 2011505210 A JP2011505210 A JP 2011505210A JP 2011518178 A5 JP2011518178 A5 JP 2011518178A5
Authority
JP
Japan
Prior art keywords
seq
composition
angiogenesis
optionally substituted
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011505210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518178A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/040848 external-priority patent/WO2009129408A2/en
Publication of JP2011518178A publication Critical patent/JP2011518178A/ja
Publication of JP2011518178A5 publication Critical patent/JP2011518178A5/ja
Pending legal-status Critical Current

Links

JP2011505210A 2008-04-16 2009-04-16 病的血管形成および脈管透過性の処置用の組成物および方法 Pending JP2011518178A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4558008P 2008-04-16 2008-04-16
US61/045,580 2008-04-16
US7388008P 2008-06-19 2008-06-19
US61/073,880 2008-06-19
PCT/US2009/040848 WO2009129408A2 (en) 2008-04-16 2009-04-16 Compositions and methods for treating pathologic angiogenesis and vascular permeability

Publications (2)

Publication Number Publication Date
JP2011518178A JP2011518178A (ja) 2011-06-23
JP2011518178A5 true JP2011518178A5 (enExample) 2012-07-26

Family

ID=41199735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011505210A Pending JP2011518178A (ja) 2008-04-16 2009-04-16 病的血管形成および脈管透過性の処置用の組成物および方法

Country Status (8)

Country Link
US (1) US20100222401A1 (enExample)
EP (1) EP2262524A4 (enExample)
JP (1) JP2011518178A (enExample)
KR (1) KR20100133881A (enExample)
CN (1) CN101687014A (enExample)
BR (1) BRPI0903901A2 (enExample)
CA (1) CA2693001A1 (enExample)
WO (1) WO2009129408A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600451A (zh) 2006-12-11 2009-12-09 犹他大学研究基金会 用于治疗病理性血管生成和血管通透性的组合物和方法
US8620879B2 (en) * 2009-10-13 2013-12-31 Google Inc. Cloud based file storage service
US20110087603A1 (en) * 2009-10-13 2011-04-14 Google Inc. Cloud based media player and offline media access
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用
CA2739107C (en) 2010-06-15 2022-12-06 The Hospital For Sick Children Methods and uses for inhibiting platelet coagulation comprising slit protein
US10561707B2 (en) * 2013-09-08 2020-02-18 Technion Research And Development Foundation Ltd. Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
EP3148986A4 (en) * 2014-05-27 2018-01-10 Navigen, Inc. Arf6 inhibitors and methods of synthesis and use thereof
JP6896641B2 (ja) * 2015-03-02 2021-06-30 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 血管新生阻害ペプチド
CN105726534A (zh) * 2016-02-17 2016-07-06 上海交通大学医学院附属仁济医院 SecinH3在制备抑制胃酸分泌药物中的应用
US10883108B2 (en) 2016-03-31 2021-01-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
CN108929383B (zh) * 2017-05-26 2021-10-15 阿思科力(苏州)生物科技有限公司 重组Slit2D2(C386S)-HSA融合蛋白及其在预防和/或治疗肺部炎症中的应用
US11077422B2 (en) * 2017-06-16 2021-08-03 Aquablok, Ltd. Spalling composite particles and methods of using them
CN108364289B (zh) * 2018-03-02 2021-05-14 成都斯斐德科技有限公司 Ivoct图像易损斑块自动检测方法
CN108715862A (zh) * 2018-05-28 2018-10-30 上海海洋大学 ddx19基因缺失斑马鱼突变体的制备方法
CA3154805A1 (en) * 2019-10-18 2021-04-22 Iosif PEDIADITAKIS Brain-chip modeling neurodegeneration and neuroinflammation in parkinson's disease
CA3171779A1 (en) * 2020-03-14 2021-09-23 Levon Michael Khachigian Compounds and pharmaceutical compositions for reducing vascular permeability,neovascularisation,angiogenesis,inflammation,cell migration and/or cell proliferation,and to methods for inhibiting fosb/.delta.fosb expression and/or erk1/2 phosphorylation and/or vcam-1 expression.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480975A (en) * 1994-02-08 1996-01-02 Brigham And Women's Hospital Induction of vascular endothelial growth factor (VEGF) by transition metals
US6372958B1 (en) * 1999-05-26 2002-04-16 The University Of Utah Research Foundation Transgenic mouse with endogenous endoglin gene disruption
US20030082586A1 (en) * 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
EP1307557A2 (en) * 2000-08-02 2003-05-07 The Johns Hopkins University Endothelial cell expression patterns
DK1572169T3 (da) * 2002-03-08 2013-10-21 Shanghai Inst Biol Sciences Påvisning og modulering af Slit- og Robo-medieret angiogenese og anvendelser deraf
AU2003247828B2 (en) * 2002-06-27 2010-05-20 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
DE102004055998A1 (de) * 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
DE102006054205A1 (de) * 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
CN101600451A (zh) * 2006-12-11 2009-12-09 犹他大学研究基金会 用于治疗病理性血管生成和血管通透性的组合物和方法
US20120129757A1 (en) * 2008-12-12 2012-05-24 Dean Li Compositions and methods for promoting vascular barrier function and treating pulonary fibrosis

Similar Documents

Publication Publication Date Title
RU2017122364A (ru) N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина
JP2017503803A5 (enExample)
JP2013509431A5 (enExample)
JP2013510125A5 (enExample)
JP2016539180A5 (enExample)
JP2019517464A5 (enExample)
JP2017528486A5 (enExample)
JP2014513110A5 (enExample)
JP2021523887A (ja) XIIa因子インヒビター
CN114026072A (zh) 治疗特发性肺纤维化的方法
JP6579714B2 (ja) 化合物
EP1682140A2 (en) Methods of use of thrombin receptor antagonists
JP2016531871A5 (enExample)
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
RU2016112542A (ru) Новые активаторы растворимой гуанилатциклазы и их применение
MX2013008749A (es) Agente terapeutico o profilactico para caquexia.
JP2018525371A5 (enExample)
JP2018525425A5 (enExample)
CA3011800A1 (en) Methods for treating cancer
JP2014506582A5 (enExample)
CA3001789A1 (en) Amide-substituted aromatic compounds for use in anti-angiogenic treatment
JP2017524013A5 (enExample)
JP2018502137A5 (enExample)
JP2022169780A (ja) 癌治療のためのレゴラフェニブとpd-1/pd-l1(2)阻害剤の併用
JP2022515670A5 (enExample)